#Karri Ramo

[misharoux]

31  days until the NHL season starts

#Karri Ramo #tampa bay lightning #Picture I Took #queue are you #Countdown time!

[scheifele]

#covid19hockeyhiatus

favourite games (1/2):

may 5th, 2015:

cgy vs. ana

this game is probably my all-time favourite game in flames history. in the second series in a row where the flames were the underdogs in a season full of comebacks and late game fights for their lives, they pulled off yet another comeback, and what was their eventual last one of that season.

the resilience of this roster with their never-give-up attitude was something to behold on its own.

johnny gaudreau, in his rookie season at the time, ties the game up with 19:40 on the clock and 20 seconds to go.

mikael backlund jumps off the bench on a delayed penalty call against the ducks and stands beneath the right side of the offensive blue line. he cycles the puck back and forth with dennis wideman and tj brodie and eventually shoots through a screen. 

the puck is in the net past frederik anderson. the goalie who, with minutes left in the third, appeared to allow a sam bennett goal slightly, but completely, past the red line, but was given a break by the refs and conference room in toronto when it was called “inconclusive” and was disallowed.

when asked what was going through his mind when scoring the game-winning goal, backlund states that during the series in vancouver, coach hartley had a heart-to-heart conversation with him, telling him to be a little more confident and shoot the puck. he saw the opportunity.

this season was the season johnny gaudreau, who was drafted 104th overall in 2011 and fresh off of winning the hobey baker, singlehandedly came in and dragged the flames out of a 6-year playoff drought, was robbed of the calder memorial trophy and bob hartley won the jack adams award.

here’s to better times ahead for this team.

#covid19hockeyhiatus #me: has a final in an hour #also me: doesn't know how to act and makes edits instead #also typing this made me sad #i miss this team :(( #the johnny-mony-hudz era #and colborne and stajan and when 19 was david jones' number #and when karri ramo and jonas hiller were playing INSANE #and when it was like they came back from 4-1 every single game #ughhh i just wanna see them win the c*p i just wanna see them win it ugh #i wanna see this team with the roster that includes gio mony johnny chucky backs and brodes win it #bc 5/6 of those guys have built this team to what it is now and have been here since we were battling to not be last in the pacific #ughhh :'(((((((( #calgary flames #myedits #edits101 #mine** #mygifs

[thepinerider]

Trade Deadline Options For the Wild in Net

The Wild should be looking at the trade market for a backup goaltender. Devan Dubnyk has been immensely reliable as their number one. He ranks in the league's top three for save percentage, goals-against average, wins and shutouts. However, Darcy Kuemper has not been quite as solid....

Via: http://thehockeywriters.com/goalie-trades-options-for-minnesota-wild-trade-deadline/

#Darcy Kuemper #Jhonas Enroth #Karri Ramo #Peter Budaj #Top Story

[goalhofer]

1st 10 Results Of Player Jersey #s By Sport On Google: #31

Hockey: Carey Price (Montreal Canadiens), Martin Jones (San Jose Sharks), Fredrik Andersen (Toronto Maple Leafs), Anders Nilsson (Buffalo Sabres), Chad Johnson (Buffalo Sabres), Chad Johnson (Calgary Flames), Carey Price (2018 NHL All-Stars), Philipp Grubauer (Washington Capitals), Anton Forsberg (Chicago Blackhawks) & Karri Ramo (Calgary Flames).

Baseball: Max Scherzer (Washington Nationals), Aaron Hicks (New York Yankees), Lance Lynn (St. Louis Cardinals), Ubaldo Jimenez (Baltimore Orioles), Joc Pederson (2015 MLB All-Stars), Ferguson Jenkins; Jr. (Chicago Cubs), Jeff Locke (Miami Marlins), Dave Winfield (San Diego Padres), Greg Maddux (Atlanta Braves) & Max Scherzer (2017 MLB All-Stars).

Basketball: Reggie Miller (Indiana Pacers), Kurt Rambis (Los Angeles Lakers), Terrence Ross (Orlando Magic), Nene (Denver Nuggets), Reggie Miller (University Of California, Los Angeles Bruins), Mike Muscala (Atlanta Hawks), Terrence Ross (Toronto Raptors), Donte "Hammer" Harrison (Harlem Globetrotters), Jarrett Allen (Brooklyn Nets) & Caron Butler (Detroit Pistons).

Football: Paul Posluszny (Pennsylvania State University Nittany Lions), Kam Chancellor (Seattle Seahawks), Byron Jones (Dallas Cowboys), Byron Maxwell (Philadelphia Eagles), David Johnson (Arizona Cardinals), Marcus Cooper (Chicago Bears), Priest Holmes (Kansas City Chiefs), Neiko Thorpe (Oakland Raiders), D.J. Hayden (Detroit Lions) & Mike Hilton (Pittsburgh Steelers).

Soccer: Ederson De Moraes (Manchester City F.C.), Damion Lowe (Seattle Sounders), Nemanja Matic (Manchester United F.C.), Bastian Schweinsteiger (Manchester United F.C.), Sead Kolasinac (Arsenal F.C.), Edimilson Fernandes (West Ham United F.C.), Luis Robles (New York Red Bulls), Kevin Volland (Bayer 04 Leverkusen Fussball G.M.B.H.), Brian Lenihan (Hull City F.C.) & Ruben Yanez (Real Madrid F.C.).

#Jerseys #Sports #Hockey #NHL #Baseball #MLB #Basketball #NBA #Football #Soccer #Celebrities #Pennsylvania #Washington Nationals #Missouri #Virginia #Indiana Pacers #New York Yankees #Hockey Goalies #Canada #British Columbia #Indiana #Connecticut #South Carolina #U.K. #Brazil #Orlando Magic #Oregon #Maryland #Tennessee #Iowa

[stocksnewsfeed]

Multiple Presentations to Showcase Glaukos Products at 2019 European Society of Cataract and Refractive Surgeons Congress

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its products will be included in various presentations at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), which begins Saturday, September 14, 2019 at the Paris Expo, Porte de Versailles in Paris, France.

Glaukos will sponsor a symposium entitled “Introducing iStent inject® W: The Trabecular Micro-Bypass Stent for Cataract Surgeons” on September 14, at 6 pm (CEST) in Pavilion 7, Room South 3. Symposium faculty includes Thomas Samuelson, MD, a U.S. surgeon who will serve as moderator; Christophe Baudouin, MD, PhD from France; Kjell Gunnar Gundersen, MD from Norway; and Fritz Hengerer, MD from Germany. Glaukos will be exhibiting on the showroom floor throughout ESCRS at booth #B105 and its products will be included in various physician presentations, including (all times CEST):

Sunday, September 15

Presented Poster Sessions – Glaucoma I and Glaucoma II Poster Village, Pod 3

10:20 am – Sustained intraocular pressure (IOP) and medication reduction after Micro-Invasive Glaucoma Surgery (MIGS) with second-generation trabecular bypass stents in open-angle glaucoma (OAG): 48-month outcomes Presenting Author: F. Aptel

10:35 am – A budget-impact analysis of the iStent inject trabecular micro-bypass system vs trabeculectomy for the treatment of glaucoma from a German payer perspective Presenting Authors: H. Falvey, A. Buchholz, P. Buchholz, S. Bluemle, C. Steeds

10:45 am – A study on outcomes of second-generation iStent inject micro-bypass with cataract surgery Presenting Authors: K. Suleiman, R. Bafiq, T. Ressiniotis

3:00 pm – Clinical effectiveness and safety of phaco combined with iStent inject G1 and iStent inject G2 in glaucoma service Presenting Authors: S. Pipis, G. Panos, A. Vergados

3:55 pm – Safety and efficacy of iStent inject trabecular micro-bypass stents during phacoemulsification for OAG associated with cataract Presenting Authors: D. Cela, E. Brasnu, P. Hamard, C. Baudouin, A. Labbe

4:00 pm – Single-surgeon experience with iStent® trabecular micro-bypass implanted in conjunction with cataract surgery: long-term outcomes Author: M. Gallardo; Presenter: P. Singh

Free Paper Session – Micro-Invasive Glaucoma Surgery Free Paper Forum, Podium 4

2:00 pm – IOP-lowering effect with the iStent inject in primary OAG eyes with or without history of previous ocular surgery Presenting Authors: F. Rufer, M. Dabiri, B. Alokla, M. Matthai, D. Holland

2:06 pm – Prospective randomized study evaluating one, two or three trabecular micro-bypass stents for OAG: five-year outcomes Presenting Author: A. Carceller Guillamet

2:12 pm – Personal experience with second-generation trabecular micro-bypass stents (iStent inject) in patients with glaucoma: four-year follow-up Presenting Author: F. Hengerer

2:36 pm – Outcomes with second-generation trabecular micro-bypass stents (iStent inject) combined with cataract surgery in patients with glaucoma: an Australian experience Presenting Authors: C. Clement, A. Ioannidis, M. Shiu, D. Manning, F. Howes

2:42 pm – Initial real-world experience with iStent inject trabecular micro-bypass stents in combination with cataract surgery Presenting Author: E. Liang

3:30 pm – Initial clinical results after implantation of second-generation trabecular micro-bypass stents (iStent inject) with cataract surgery Presenting Author: K. Gundersen

3:36 pm – My observations after almost 300 trabecular micro-bypass glaucoma surgeries with iStent inject over a period of five years Presenting Author: T. Neuhann

3:42 pm – Phacoemulsification with Stent® trabecular micro-bypass stents in complex and moderate to advanced glaucoma: three-year effectiveness and safety outcomes Presenting Authors: G. Moussa, P. Pandey, J. Panthagani, M. Kutubi, I. Masood

Monday, September 16

Free Paper Session – Glaucoma Management Free Paper Forum, Podium 4

5:36 pm – Outcomes of phacoemulsification combined with two iStent inject trabecular micro-bypass stents and endocyclophotocoagulation Presenting Authors: A. Barata, M. Georgopoulos, G. Ratnarajan

5:48 pm – A cost-utility analysis of the iStent inject trabecular micro-bypass system plus cataract surgery in patients with mild to moderate OAG in France Presenting Authors: C. Schweitzer, A. Labbe, A. Mudd, K. Nieland, J. Kleintjens, G. Gicquel, H. Falvey

E-Posters (Viewable throughout ESCRS at terminals in the Poster Village)

Budget impact analysis of the iStent inject implant for OAG treatment in Spain Authors: J. Belda, K. Schargel, M. Teus, C. Lavin, M. Soler, M. Appierto

Real-world experience with iStent inject second-generation trabecular micro-bypass combined with phacoemulsification: a Canadian study reporting one-year outcomes Author: P. Harasymowycz

One-year outcomes of trabecular micro-bypass stents with concomitant cataract surgery in primary angle closure glaucoma Authors: A. Salimi, M. Abu-Nada, P. Harasymowycz

Multi-iStent inject implantation (four stents) in OAG; a glimpse into the future Authors: M. Economou, T. Arnljots

Single U.S. surgeon’s early experience with iStent inject trabecular micro-bypass stents implanted in conjunction with cataract surgery Author: M. Gallardo

Retrospective study of our first 48 cases with two second-generation trabecular micro-bypass stents Authors: B. Gonzalez Ferrer, R. Cordero Ros, C. Lavin Dapena, A. Ramos Castrillo

The iStent implantation in combination with SLT as an effective method of lowering IOP in patients with glaucoma Authors: M. Hajduga, I. Filipecka, M. Hajduga, K. Posluszny-Rutkowska, L. Drzyzga, E. Mrukwa-Kominek

Cataract surgery with iStent inject implantation in high-risk glaucoma and ocular hypertension: six-month results Authors: Y. Leng, M. Lane, S. Dulku

Prospective evaluation of iStent inject trabecular micro-bypass implantation combined with a topical prostaglandin: four-year outcomes Author: J. Myers

Reduction in IOP and glaucoma drops after standalone iStent inject in pseudophakic eyes: nine- to 12-month results Authors: M. Pavel, A. Nagar, M. Nagar

Initial outcomes with second-generation trabecular micro-bypass stents (iStent inject) implanted in conjunction with phacoemulsification: single U.S. surgeon’s experience Author: S. Sarkisian

Pivotal study of second-generation trabecular micro-bypass stents (iStent inject) implanted in conjunction with cataract surgery: analysis by baseline IOP Author: S. Sarkisian

Evaluation of the iStent inject in pseudophakic eyes with OAG: preliminary results Authors: V. Vohra, A. Adam, C. Dineen, B. Karri, I. Madgula

Evaluation of outcomes for patients undergoing iStent inject trabecular micro-bypass for the treatment of ocular hypertension and glaucoma Authors: S. Zormpas, A. Matsou, R. Petrarca, C. Panos

iStent inject: tips and tricks (video) Authors: A. Tatham, F. Ruefer

Glaukos pioneered MIGS, which involves insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos’ MIGS devices are designed to reduce IOP by restoring the natural outflow pathways for aqueous humor. Glaukos received U.S. Food and Drug Administration (FDA) approval for its first-generation MIGS device, the iStent, in 2012. Its second-generation iStent inject, which received FDA approval in 2018, includes two stents preloaded in an auto-injection mechanism that facilitates stent insertion into multiple trabecular meshwork locations through a single corneal incision. The iStent inject is also approved in the European Union, Armenia, Australia, Brazil, Canada, Hong Kong, Singapore, South Africa and other international markets. Glaukos is pursuing FDA approval for additional MIGS surgical and sustained pharmaceutical therapy pipeline products, all of which are investigational in the United States.

About iStent inject Trabecular Micro-Bypass System (U.S.)

Indication for Use: The iStent inject Trabecular Micro-Bypass System Model G2-M-IS is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild-to-moderate primary open-angle glaucoma.

Contraindications: The iStent inject is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI Information: The iStent inject is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

Adverse Events: Common postoperative adverse events reported in the randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

For more information, visit www.glaukos.com.

About iStent Trabecular Micro-Bypass Stent (U.S.)

Indication for Use: The iStent Trabecular Micro-Bypass Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate open-angle glaucoma currently treated with ocular hypotensive medication.

Contraindications: The iStent is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings: Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details.

Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after “washout” of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.

Adverse Events: The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of ≥ 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.

Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the continued efficacy and safety profile of our products, as well as the potential applications of our products as might be suggested in the surgeon presentations referenced above. These risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and our Quarterly Report on Form 10-Q for the first quarter ended June 30, 2019. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

The post Multiple Presentations to Showcase Glaukos Products at 2019 European Society of Cataract and Refractive Surgeons Congress appeared on Stocks News Feed.

source https://stocksnewsfeed.com/businesswire/multiple-presentations-to-showcase-glaukos-products-at-2019-european-society-of-cataract-and-refractive-surgeons-congress/

#Stocks #StockMarket

[bettingtipstech-blog]

Forecast and bet on the match CSKA – "avant-garde" 15 APR 2019

New Post has been published on https://betting-tips.site/forecast-and-bet-on-the-match-cska-avant-garde-15-apr-2019/

Forecast and bet on the match CSKA – "avant-garde" 15 APR 2019

The match CSKA – “avant-garde” will take place on 15 April at 19:30 GMT in “the ice Palace CSKA” in the second match of the final series of play-offs KHL. What factor can make a bet on game CSKA vs Avangard.

CSKA

Muscovites had a great first match of the series against “Avant-garde”. The victory with the score 5:2 will definitely add to the team strength and confidence. CSKA took the lead in the match 3:0 to the middle of the second period, Shumakov most gained one goal, but CSKA has confidently brought it to victory in the third period efforts of Grigorenko, who first scored in equal structures, and then, in empty gate, having thereby a hat-trick in the match. Waiting for the second match, let’s see what the answer is “vanguard”. Injured players from CSKA there.

“Avant-garde”

The hawks first match frankly failed. CSKA was faster, had better control of the puck and combined. The players of army club was often pure ice for lethal shots than they are used. Also has not rescued by the goalkeeper. At least 1-2 scoring might help out. The only thing that pleased – this implementation superfluous. This component of the game, the hawks successfully transferred from the previous series with “Salavat”, where it worked perfectly. Today, the hawks scored 2 goals from 5 attempts. But against this CSKA is not enough. You need to add in all components of the game. Obviously, the game that “Avangard” demonstrated against “Salavat Yulaev” CSKA will not be enough.

Still appears in the list of injured goalie, Karri Ramo.

Statistics of personal meetings

CSKA increased its winning streak against “Avant-garde” to six matches. This season the army team the hawks haven’t lost. In Moscow CSKA has beaten “avant-garde” 7 times out of 8 the last. This season the teams met in the regular season twice, both won CSKA 3:2 and 4:2.

The odds on the match from the bookmaker Pari-Match

Bookmaker Pari-Match offers the following quotes on the match:

The victory of CSKA: 1,65

Draw: 4,5

Victory “Avant-Garde”: 4,5

Also, the bookmaker offers to bet on under 4.5 goals for 1.72.

Bet on the match CSKA – “avant-garde”

CSKA showed in the first match of its power, winning a landslide victory with a margin. But “vanguard” is not just got to the finals, the team is also OK. However, to compete with CSKA in this season in his ice – bad job. Almost no one does it. During the last 16 meetings at home, CSKA has only lost once, and that in overtime. Put on their victory in the second match of the series.

[misharoux]

#Vincent Lecavalier #Vinny Lecavalier #Karri Ramo #tampa bay lightning #Picture I Took #season a week #0809 #queue are you

[lajame-blog1]

01-01 Calgary Flames put Karri Ramo back in the net #CalgaryFlames http://dlvr.it/Q8RPDH

#Calgary Flames

[nicolealexaa-blog]

Calgary Flames put Karri Ramo back in the net #CalgaryFlames #CalgaryFlames http://dlvr.it/Q78DQt

#Calgary Flames

[anniegooo-blog]

Calgary Flames put Karri Ramo back in the net #CalgaryFlames #CalgaryFlames http://dlvr.it/Q75TpL

#Calgary Flames

[goalhofer]

2018 Olympics Finland Roster

Alpine Skiing

Andreas Romar (Korsholm)

Samu Torsti (Vaasa)

Biathlon

Tero Seppala (Ristijarvi)

Tuomas Gronman (Kouvola)

Olli Hiidensalo (Nummi-Pusula)

Venla Lehtonen (Kontiolahti)

Suvi Minkkinen (Lapinlahti)

Mari Laukkanen (Eno)

Kaisa-Leena Makarainen (Ristijarvi)

Laura Toivanen (Joensuu)

Cross Country Skiing

Matti Heikkinen (Vantaa)

Perttu Hyvarinen (Kuopio)

Lari Lehtonen (Imatra)

Iivo Niskanen (Oulu)

Lauri Vuorinen (Rovaniemi)

Ristomatti Hakola (Jami)

Martti Jylha (Helsinki)

Johanna Matintalo (Rovaniemi)

Laura Mononen (Hiihtoseura)

Kerttu Niskanen (Oulu)

Krista Parmakoski (Urheilijat)

Aino-Kaisa Saarinen (Kisa)

Freestyle Skiing

Joona Kangas (Levi)

Jussi Penttala (Helsinki)

Jimi Salonen (Muurame)

Anni Karava (Helsinki)

Nordic Combined

Arttu Makiaho (Kaajani)

Ilkka Herola (Siilinjarvi)

Eero Hirvonen (Laukaa)

Hannu Manninen (Rovaniemi)

Leevi Mutru (Lahti)

Ski Jump

Antti Aalto (Sotkamo)

Janne Ahonen (Lahti)

Andreas Alamommo (Helsinki)

Jarkko Maatta (Iisalmi)

Eetu Nousiainen (Helsinki)

Julia Kykkanen (Lahti)

Curling

Oona Kauste (Espoo)

Tomi Rantamaki (Helsinki)

Figure Skating

Emmi Peltonen (Helsinki)

Speed Skating

Pekka Koskela (Mantta)

Mika Poutala (Helsinki)

Elina Risku (Seinajoki)

Hockey

Lauri Marjamaki (Tampere)

Mikko Koskinen (Vantaa)

Karri Ramo (Asikkala)

Juha Metsola (Tampere)

Mikko Lehtonen (Turku)

Tommi Kivisto (Vantaa)

Lasse Kukkonen (Oulu)

Sami Lepisto (Espoo)

Juuso Hietanen (Hameenlinna)

Miro Heiskanen (Espoo)

Miika Koivisto (Vaasa)

Atte Ohtamaa (Nivala)

Marko Anttila (Lempaala)

Julius Junttila (Oulu)

Eeli Tolvanen (Vihti)

Joonas Kemppainen (Kajaani)

Jani Lajunen (Espoo)

Jonas Enlund (Helsinki)

Petri Kontiola (Seinajoki)

Mika Pyorala (Oulu)

Jarno Koskiranta (Paimio)

Oskar Osala (Vasaa)

Sakari Manninen (Oulu)

Teemu Hartikainen (Kuopio)

Jukka Peltola (Tampere)

Veli-Matti Savinainen (Espoo)

Eveliina Suonpaa (Kiukainen)

Meeri Raisanen (Tampere)

Noora Raty (Espoo)

Isa Rahunen (Kuopio)

Rosa Lindstedt (Ylojarvi)

Jenni Hiirikoski (Lempaala)

Mira Jalosuo (Lieksa)

Ella Viitasuo (Lahti)

Minnamari Tuominen (Helsinki)

Ronja Savolainen (Helsinki)

Venla Hovi (Tampere)

Linda Valimaki (Ylojarvi)

Anniina Rajahuhta (Helsinki)

Riikka Valila (Jyvaskyla)

Petra Nieminen (Tampere)

Emma Nuutinen (Vantaa)

Sara Sakkinen (Tampere)

Saila Saari (Alavus)

Michelle Karvinen (Espoo)

Tanja Niskanen (Juankoski)

Susanna Tapani (Laitila)

Snowboarding

Kalle Jarvilehto (Vuokatti)

Rene Rinnekangas (Vuokatti)

Janne Korpi (Vihti)

Markus Malin (Lahti)

Peetu Piiroinen (Hyvinkaa)

Roope Tonteri (Valkeala)

Anton Lindfors (Porvoo)

Enni Rukajarvi (Kuusamo)

#Sports #Winter #Races #Hockey #Hockey Goalies

[teresabarnn-blog]

Calgary Flames put Karri Ramo back in the net #CalgaryFlames http://dlvr.it/Q75NgB

#Calgary Flames

[ceciliacro-blog]

12-07 Calgary Flames put Karri Ramo back in the net #CalgaryFlames http://dlvr.it/Q4tf8r

#Calgary Flames

[paulaphill-blog]

Calgary Flames put Karri Ramo back in the net #CalgaryFlames http://dlvr.it/Q3wN9t

#Calgary Flames

[isabelglo-blog]

Flames put goaltender Karri Ramo on injured list, call up Joni Ortio #CalgaryFlames http://dlvr.it/Q3t6tP

#Calgary Flames

[misharoux]

31 days to go!

#Karri Ramo #COUNTDOWN BITCHES